A federal consultative group voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is advisory only. The FDA has given no signal on whether it will take up the recommendation. The move came after weeks of open hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could shift how the agency handles a part of the wellness market that is moving at speed. Watchers are waiting to see if the FDA follows through on the vote. A spokesperson offered no fixed date for a response. Industry voices argue the change would widen access to substances some say help. Opponents warn that looser rules could allow poor oversight across a wide-open market. The advisory vote only plants the seed for a shift, and the last word rests with the federal regulator.